5. References

  1. DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: http://www.micromedexsolutions.com.libproxy.uthscsa.edu/. Accessed November 23, 2021.
  2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2017. Available at: http://www.clinicalpharmacology-ip.com.ezproxy.lib.utexas.edu/. Accessed November 23, 2021.
  3. Facts and Comparisons eAnswers [database online]. Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.; 2021. Available at: https://fco-factsandcomparisons-com.ezproxy.lib.utexas.edu. Accessed November 23, 2021. 
  4. American Society of Health-System Pharmacists. 2021. AHFS Drug Information® - 2021st Ed. Bethesda, MD. American Society of Health-System Pharmacists®. STAT!Ref Online Electronic Medical Library. Available at:  https://online.statref.com/document/cQfe8yqMRNqgSGqm4Qo8Qj. Accessed November 23, 2021. 
  5. Gabapentin (Neurontin®) package insert. Pfizer, October 2021.
  6. Gabapentin extended-release tablets (Gralise®) package insert. Almatica Pharma LLC, February 2021.
  7. Gabapentin enacarbil extended-release tablets (Horizant®) package insert. Arbor Pharmaceuticals, LLC, September 2021.
  8. The US Gabapentin Study Group. The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. Epilepsy Res. 1994;18(1):67–73. 
  9. Appleton R, Fichtner K, LaMoreaux L, et al. Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study. Gabapentin Paediatric Study Group. Epilepsia. 1999;40(8):1147–54. 
  10. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. Gabapentin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2000;(3):CD001415. 
  11. Ortega E. Postherpetic neuralgia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com (Accessed on November 23, 2021.)
  12. Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6(6):CD007938. Published 2017 Jun 9. doi:10.1002/14651858.CD007938.pub4.
  13. Johnson RW, Rice AS. Clinical practice. Postherpetic neuralgia. N Engl J Med. 2014;371(16):1526-33. 
  14. Trenkwalder C, Allen R, Högl B, et al. Comorbidities, treatment, and pathophysiology in restless legs syndrome. Lancet Neurol. 2018;17(11):994–1005. doi:10.1016/S1474-4422(18)30311-9.
  15. Kim ES, Deeks ED. Gabapentin enacarbil: a review in restless legs syndrome. Drugs. 2016;76(8):879–87.